Simulations Plus, Inc. (AMEX: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has received a purchase order from the U.S. National Institutes of Health (NIH) for its best-in-class ClassPharmer software product.

“It’s been a busy final week of our fourth fiscal quarter. This license for the National Institutes of Health follows the announcement yesterday of the FDA licenses for GastroPlus™ and DDDPlus™, and it adds another important government agency to our list of customers,” said Ron Creeley, vice president of marketing and sales for Simulations Plus. “We believe these agencies serve as trend-setting organizations and examples to companies who work in pharmaceutical research and development.”

Walt Woltosz, chairman and chief executive officer of Simulations Plus, said: “We acquired ClassPharmer 3.5 and ChemTK™ almost two years ago, and merged them into the new ClassPharmer 4.X versions. The dramatic improvement in performance of the new version has caught the attention of chemists worldwide, and ClassPharmer is now a major contributor to our revenues and earnings. We have evolved its capabilities into molecule design as well, with the release earlier this year of the R-Table Exploder feature. Together with our ADMET Predictor™ software, the combination now enables chemists to evaluate molecules they have already synthesized, as well as to automatically generate new molecules and evaluate them for a variety of important properties. We believe our continuously evolving capability to design new molecules in conjunction with ADMET estimation is an effective formula for fueling the growth of Simulations Plus.”